A. Ogden

发表

First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430

Yiyun Huang, R. Carson, J. Ropchan, 2016, The Journal of Nuclear Medicine.

Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.

J. Pandit, C. Whitehead, Cindy Spessard, 2013, Bioorganic & medicinal chemistry letters.

0162819 , a Biotin 1 Carboxylase Inhibitor Representing a New Class of Antibacterial Compounds , Using In Vitro 2 Infection Models 3 4 5 Running Title : PK / PD Characterization : Novel Biotin Carboxylase Inhibitor 6 7 8

M. Kuhn, D. Hanna, Shawn M Mehrens, 2011 .

Evaluation of Pharmacokinetic/Pharmacodynamic Relationships of PD-0162819, a Biotin Carboxylase Inhibitor Representing a New Class of Antibacterial Compounds, Using In Vitro Infection Models

M. Kuhn, D. Hanna, Shawn M Mehrens, 2011, Antimicrobial Agents and Chemotherapy.

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

J. Grosset, C. K. Stover, S. Tyagi, 2009, American journal of respiratory and critical care medicine.

Photosensitive epilepsy

Donal N. Gorman, D. Friedman, G. Krauss, 2019, Neurology.

Suramin as a Chemosensitizer: Oral Pharmacokinetics in Rats

J. Au, M. Wientjes, A. Ogden, 2004, Pharmaceutical Research.

Pentostatin in steroid-refractory acute graft-versus-host disease.

M. Grever, J. Byrd, J. Bolaños-Meade, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The histamine skin prick test: An analysis of the method for use in clinical trials.

M. Bednar, D. Volfson, A. Ogden, 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore

Alla Karnovsky, J Richard Miller, V Hayden Thomas, 2009, Proceedings of the National Academy of Sciences.

Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.

Howard Miller, J. Pandit, C. Whitehead, 2013, Bioorganic & medicinal chemistry letters.

Chemosensitization of pancreatic tumors with the use of low-dose suramin

A. Ogden, 2004 .

First-inHuman Assessment of the Novel PDE 2 A PET Radiotracer 18 FPF-05270430

Yiyun Huang, R. Carson, J. Ropchan, 2016 .

Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model

H Geerts, H. Geerts, T. Comery, 2014, CPT: pharmacometrics & systems pharmacology.

A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia.

E. Pickering, C. J. Schmidt, N. DeMartinis, 2019, Journal of clinical psychopharmacology.

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

J. Pandit, W. Hoffman, M. Hajós, 2018, Journal of medicinal chemistry.

In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects

P. Fazio, O. Vitolo, C. Halldin, 2017, Neuropharmacology.

First-inHuman Studies of Brain PDE 2 A First in Human Assessment of the Novel PDE 2 A PET Radiotracer 18 FPF-05270430

Yiyun Huang, R. Carson, J. Ropchan, 2016 .

First-in-Human Studies of Brain PDE2A

Yiyun Huang, R. Carson, J. Ropchan, 2016 .

J06 A randomized, double-blind, placebo-controlled phase ii efficacy and safety study of the PDE10A inhibitor PF-02545920 in huntington disease (amaryllis)

R. Reilmann, M. Delnomdedieu, Z. Berger, 2018, Clinical therapeutics.